PharmaTelevision - Intersuisse Bioscience Managers: Investments and Australian Biotech

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Intersuisse Bioscience Managers: Investments and Australian Biotech

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Matt McNamara, Chief Investment Officer at Intersuisse Bioscience Managers.

Filmed at AusBiotech 2009, they discuss:

• the companies Intersuisse invests in
• private v. public companies and Australia v. New Zealand from an investment point of view
• the importance of funds
• how Australian biotech is likely to perform in 2010

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The companies Intersuisse Bioscience Managers invests in and Private v. public companies.

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Melbourne, Australia. On this show, I have Matt McNamara, who is the Chief Investment Officer at Intersuisse Bioscience Managers, welcome.

Matt McNamara:

Yeah.

Fintan Walton:

Matt , you are an investor in the biotech scene; you've got a fund that you've raised relatively recently.

Matt McNamara:

Correct.

Fintan Walton:

What is your fund investing in?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Matt McNamara
Chief Investment Officer
Intersuisse Bioscience Managers

Matt is responsible for deal flow management and evaluation, leading all investment recommendations and due diligence. He has over 20 years experience in the Life Sciences sector. After initially being a Molecular Biology Research Assistant, Matt spent 11 years in Sales & Marketing, and General Management with Merck & Co. and Johnson and Johnson Medical Pty. Ltd. respectively. He has served as SVP Business Development for a University of Sydney spin out, eBioinformatics Inc. and was CEO of a Life Sciences Venture Capital fund, SciCapital Pty. Ltd.

Intersuisse Bioscience Managers Pty Ltd (IB Managers)

Intersuisse Bioscience Managers Pty Ltd (IB Managers), the Australian operation of International Bioscience Managers Limited (UK), was established in 2003, bringing together in Australia the essential elements of an international advisory and funds management group ("Bioscience Managers") Bioscience Managers is unique in Australia bringing an international perspective together with the track record, networks and expertise required to convert that perspective into informed investment decisions and value enhancing opportunities. Bioscience Managers offers a multi-disciplined team and related activities in the northern hemisphere.

The IB Australian Bioscience Fund I, is a private equity style Life Science fund that will raise up to $100 million, based in Victoria and draw on the global resources of the Bioscience Managers network.

Bioscience Managers is currently assisting a number of Australian life science companies identify and implement commercialisation strategies. It has established working practices that have created an active deal log and benchmarks to assist Australian companies achieve international best practice.